TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

47 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Dementia / Alzheimer'sParkinson's disease

    Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments

    Testing whether a tributyrin supplement helps memory, thinking, and balance in adults with Parkinson

    📍 Domino's Farms · Ann Arbor, MI · Get directions →

    The goal of this clinical trial is to learn if taking a tributyrin supplement works to improve memory and thinking and walking and balance in adults with Parkinson disease Parkinson disease dementia. It will also learn about the safety of tributyrin supplementation.

    ✓ Study care freePhase 1Ages 45+Learn more →
  • Parkinson's disease

    Virtual tES Device Treatment for Parkinson's Disease Motor Symptoms

    Testing a non-invasive brain stimulation device to improve Parkinson’s movement problems

    📍 U LLC Headquarters · Cleveland, OH · Get directions →

    This study tests a new, non-invasive brain stimulation device called Sphere V3.0 to help improve movement problems in people with Parkinson's disease. The device delivers gentle electrical signals to the scalp using small electrodes placed on the head.

    ✓ Study care freePhase 1Ages 18–80Learn more →
  • Parkinson's disease

    Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis

    Testing whether a low-dose seizure medicine can help Parkinson’s psychosis

    📍 Johns Hopkins · Baltimore, MD · Get directions →

    This clinical trial will test whether AGB101 (low-dose levetiracetam, 220 mg, extended release tablet) can improve symptoms of psychosis in Parkinson's disease. Participants will be asked to complete up to 5 in-person study visits over approximately 20 weeks.

    ✓ Study care freePhase 2Ages 40–85Learn more →
  • High blood pressureKidney disease

    📍 Research Site · Surprise, AZ · +17 more US sites · Get directions →

    International, Multicenter and Double-Blind study. The purpose is to measure the effect of baxdrostat in combination with dapagliflozin compared with baxdrostat/placebo on albuminuria, as well as safety, in participants with chronic kidney disease and high blood pressure.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Parkinson's disease

    A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

    Testing a treatment in people with early Parkinson’s disease who have an LRRK2 gene test result

    📍 Banner Sun Health Research Institute · Sun City, AZ · +39 more US sites · Get directions →

    The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic profile. A DNA test will be used to identify the "LRRK2-driven" population with predicted elevation in the LRRK2 pathway.

    ✓ Study care freePhase 2Ages 40–80Learn more →
  • Parkinson's disease

    A Study of Buntanetap in Participants With PD

    Testing the long-term safety of buntanetap in people with Parkinson’s

    📍 University of Alabama at Birmingham · Birmingham, AL · +26 more US sites · Get directions →

    This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study.

    ✓ Study care freePhase 2Ages 40–85Learn more →
  • Type 2 diabetesHigh blood pressure

    Polypill for Prevention of Cardiomyopathy

    Testing a pill combination to prevent heart muscle disease in people with type 2 diabetes and high

    📍 UT Southwestern Medical Center · Dallas, TX · Get directions →

    This study will investigate the utility of a polypill-based strategy for patients with type 2 diabetes mellitus and high risk of heart failure (HF), as assessed via the WATCH-DM risk score. Polypill therapy will consist of empagliflozin 12.5 mg, losartan 25, 50 or 100 mg, and finerenone 10 mg daily.

    ✓ Study care freePhase 1Ages 18–100Learn more →
  • Heart / cardiovascular disease

    Improving Coronary Vascular Health in Women

    Testing whether blood flow in heart arteries can be improved in women with HIV

    📍 Massachusetts General Hospital · Boston, MA · Get directions →

    Women with HIV have an increased risk of having a myocardial infarction (heart attack) as compared to women without HIV. One of the mechanisms underlying the increased risk of myocardial infarction among women with HIV may involve reduced ability to increase blood flow through large and small coronary arteries at times when increased flow of oxygen-carrying blood is needed.

    ✓ Study care freePhase 2Ages 45–75WomenLearn more →
  • DepressionParkinson's disease

    Imaging Depression in Parkinson's Disease

    Studying brain changes linked to depression in people with Parkinson’s

    📍 Yale University · New Haven, CT · Get directions →

    The goal of this observational study is to identify targetable neural substrates of depression in Parkinson's Disease for the first time in people with Parkinson's between the ages of 40 and 80, who are experiencing symptoms of depression.

    ✓ Study care freePhase 2Ages 40–80Learn more →
  • High blood pressureCOPD (chronic lung disease)

    Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH

    Testing tadalafil to see if it improves shortness of breath in COPD with high blood pressure in the

    📍 Rocky Mountain Regional VA Medical Center, Aurora, CO · Aurora, CO · +4 more US sites · Get directions →

    The investigators will study whether the drug tadalafil improves shortness of breath in 126 Veterans with Chronic Obstructive Pulmonary Disease (COPD) and high blood pressure in the lungs. The investigators will also assess whether tadalafil improves quality of life, home daily physical activity, exercise endurance, the frequency of acute flares of COPD, blood pressure in the lungs, and lung function.

    ✓ Study care freePhase 2Ages 35–89Learn more →
  • Parkinson's disease

    Ketamine for Veterans With Parkinson's Disease

    Testing ketamine for depression in veterans with Parkinson’s disease

    📍 San Francisco VA Medical Center, San Francisco, CA · San Francisco, CA · Get directions →

    Parkinson's disease (PD) is a devastating illness that has a growing impact on Veterans. One of the most disabling symptoms is depression, which is common in PD and linked to poor quality of life and higher risk of suicide.

    ✓ Study care freePhase 2Ages 40–80Learn more →
  • Parkinson's disease

    Early Longitudinal Imaging in the Parkinson's Progressive Marker Initiative (PPMI) Using (18F)AV-133 (PPMI AV-133 Prodromal Imaging)

    Tracking how brain scans change over time in people with early Parkinson’s

    📍 Institute for Neurodegenerative Disorders · New Haven, CT · +1 more US site · Get directions →

    The study is a longitudinal, multi-center study to assess progression of \[18F\] AV-133 imaging in Prodromal PD participants. Participants will be followed for up to 24 months.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • DepressionParkinson's disease

    Psilocybin Therapy for Depression in Parkinson's Disease

    Testing whether psilocybin therapy improves depression symptoms in people with Parkinson’s disease

    📍 University of California, San Francisco · San Francisco, CA · Get directions →

    The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.

    ✓ Study care freePhase 2Ages 40–80Learn more →
  • High blood pressureDementia / Alzheimer's

    Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)

    Testing whether tightly lowering high blood pressure slows brain changes tied to Alzheimer’s

    📍 University of Texas Southwestern Medical Center · Dallas, TX · Get directions →

    The purpose of this study is to determine if intensive lowering of systolic blood pressure (SBP), using FDA approved medications (antihypertensive), reduces Alzheimer's Disease pathology (i.e., excessive brain amyloid and tau protein deposition) in older adults at high risk for memory decline or dementia.

    ✓ Study care freePhase 2Ages 60–85Learn more →
  • Parkinson's disease

    A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)

    Testing the safety and effect of a gene therapy put into the brain for moderate Parkinson’s disease

    📍 Mayo Clinic · Phoenix, AZ · +33 more US sites · Get directions →

    The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.

    ✓ Study care freePhase 2Ages 45–75Learn more →
  • Heart / cardiovascular diseaseLupus (SLE)

    The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD

    Testing whether anifrolumab improves blood vessel risk markers in lupus

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: People with systemic lupus erythematosus (SLE) are at risk of developing complications in their blood vessels. This can increase the risk of heart attacks or stroke.

    ✓ Study care freePhase 2Ages 18–80Learn more →
  • Parkinson's disease

    Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease

    Testing an oral low-dose carbon monoxide liquid in people with Parkinson’s

    📍 Quest Research Institute · Farmington Hills, MI · Get directions →

    A phase 2a multicenter, randomized, double-blind, placebo-controlled multiple dose study to evaluate the safety, tolerability, pharmacokinetics, of HBI-002, an oral low-dose carbon monoxide (CO) liquid drug product, administered daily over 14 days in subjects with Parkinson's disease (PD).

    ✓ Study care freePhase 2Ages 40–80Learn more →
  • Parkinson's disease

    Pyridostigmine for the Treatment of Constipation in Parkinson Disease

    Testing pyridostigmine as a treatment for constipation in Parkinson disease

    📍 University of Vermont Medical Center · Burlington, VT · Get directions →

    Constipation is a common and debilitating non-motor symptom of Parkinson disease (PD) that often precedes the onset of classic motor symptoms by decades. There is no standardized algorithm for managing constipation in this patient population, nor are there dedicated treatments.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Parkinson's disease

    Rehabilitation of Airway Protection in Parkinson's Disease

    Testing therapy to improve airway protection problems in Parkinson’s

    📍 Purdue University · West Lafayette, IN · +1 more US site · Get directions →

    Airway protective disorders are a prevalent and progressive consequence of Parkinson's Disease (PD), and often result in aspiration pneumonia which is the leading cause of death in PD. Despite this, a large number of patients with PD do not access specialized services to address these critical deficits.

    ✓ Study care freePhase 2Ages 50–90Learn more →
  • Obesity / overweightHigh blood pressureCOPD (chronic lung disease)

    Feasibility of Semaglutide in Advanced Lung Disease

    Testing whether semaglutide can be given safely to people with advanced lung disease

    📍 University of Pennsylvania Perelman School of Medicine · Philadelphia, PA · Get directions →

    The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease. The main question\[s\] it aims to answer are: 1.

    ✓ Study care freePhase 1Ages 18–80Learn more →
  • Parkinson's disease

    📍 Cornell University Weill Medical College · New York, NY · Get directions →

    This is a phase 1/2 clinical study to evaluate the safety, tolerability, feasibility, and preliminary efficacy of NouvNeu001 in patients with advanced Parkinson's Disease.

    ✓ Study care freePhase 1Ages 30–75Learn more →
  • Dementia / Alzheimer'sParkinson's disease

    18F-mFBG Cardiac Uptake With Lewy Body Dementia

    Testing a heart imaging tracer to see how Lewy body dementia affects nerve signals

    📍 Houston Methodist Neurological Institute · Houston, TX · Get directions →

    This is a Phase 2 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for quantification of the effect of neurodegenerative diseases on myocardial sympathetic innervation. Effectiveness of 18F-mFBG imaging of the heart will be judged in terms of the quantitative difference between results for subjects with Lewy body and non-Lewy body neurologic disease as compared to historical data for healthy control subjects.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Parkinson's disease

    Tenapanor in Synucleinopathy-Related Constipation

    Testing tenapanor for constipation related to Parkinson’s disease

    📍 Cedar Valley Digestive Health Center · Waterloo, IA · Get directions →

    Investigation of tenapanor as a potential treatment for synucleinopathy-associated constipation

    ✓ Study care freePhase 2Ages 50–89Learn more →
  • Parkinson's disease

    Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease

    Testing how much brain tau buildup is in people with Parkinson’s using PET scans

    📍 Institute for Neurodegenerative Disorders / XingImaging, LLC · New Haven, CT · Get directions →

    The study aims to evaluate the burden of tau pathology in people with Sporadic and LRRK2 PD via in vivo imaging using the tau tracer, \[18F\]PI-2620, and a high resolution PET camera, NeuroEXPLORER.

    ✓ Study care freePhase 2Ages 45–85Learn more →
  • Parkinson's disease

    A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

    Testing two doses of an add-on medicine to levodopa for Parkinson’s with motor fluctuations

    📍 University of Arkansas for Medical Sciences · Little Rock, AR · +24 more US sites · Get directions →

    This is a Phase 2 study in people with Parkinson's disease who experience motor fluctuations while taking levodopa. The study will evaluate how effective two different doses of the study drug AP-472 are when added to levodopa treatment, compared with a placebo.

    ✓ Study care freePhase 2Ages 30–80Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors

    Testing how BGE-102 affects inflammation blood tests and safety in people with obesity and heart

    📍 Site 108 · Chandler, AZ · +11 more US sites · Get directions →

    The purpose of this study is to learn about the effects of BGE-102 on blood biomarkers including hsCRP, which is a lab value used to measure inflammation. BGE-102 decreases inflammation which may improve obesity and cardiovascular health.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • High blood pressureKidney disease

    Equol and Vascular Function in Women With Chronic Kidney Disease

    Testing whether equol affects blood vessel function in women with chronic kidney disease

    📍 University of Colorado Anschutz Medical Campus · Aurora, CO · Get directions →

    The risk of cardiovascular disease (CVD) is significantly elevated in patients with chronic kidney disease (CKD). Notably, women with CKD commonly experience menstrual disturbances induced by CKD, which may contribute to impaired vascular function and elevated CVD risk.

    ✓ Study care freePhase 2Ages 50+WomenLearn more →
  • Obesity / overweightHeart / cardiovascular disease

    Mechanisms of Semaglutide Therapy in Heart Failure Patients

    Testing how semaglutide works in people with heart failure and obesity

    📍 Greenstone Biosciences · Palo Alto, CA · +1 more US site · Get directions →

    Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, primarily used for treatment of type-2 diabetes mellitus. GLP-1 receptors are present on pancreatic islet β-cells, δ-cells and α-cells.

    ✓ Study care freePhase 1Ages 20–80Learn more →
  • Parkinson's disease

    rTMS to Improve Cognition in Parkinson's

    Testing whether noninvasive brain stimulation can improve thinking in people with Parkinson’s

    📍 Jesse Brown VA Medical Center, Chicago, IL · Chicago, IL · +1 more US site · Get directions →

    The purpose of this study is to examine safety, feasibility, and the behavioral and brain effects of a non-invasive treatment, repetitive transcranial magnetic stimulation (rTMS), for Veterans with Parkinson's disease or atypical parkinsonism and mild impairments in their thinking. The hypothesis is that rTMS can improve thinking for people with Parkinson's disease or atypical parkinsonism who are experiencing mild problems with their thinking ability.

    ✓ Study care freePhase 1Ages 50+Learn more →
  • Parkinson's disease

    Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease

    Testing a wearable sensor that gives feedback for swallowing therapy in Parkinson’s

    📍 Purdue University · West Lafayette, IN · Get directions →

    Dysphagia, or difficulty swallowing, is a common symptom of many neurological diseases but its treatment is not well established or easily accessible. To start addressing this gap, the researchers developed and validated a cost-effective wearable surface electromyography (sEMG) biofeedback sensor technology (i-Phagia), optimized to record muscle activity from the head/neck and provide biofeedback to patients and adherence data to clinicians during swallow therapy.

    ✓ Study care freePhase 2Ages 50–90Learn more →
  • Parkinson's disease

    Reducing Falls With Varenicline in Hypocholinergic Parkinson Disease

    Testing varenicline to reduce falls and improve walking multitasking in Parkinson’s

    📍 University of Michigan · Ann Arbor, MI · Get directions →

    This trial aims to test whether one year of Varenicline, when compared to placebo, can reduce fall risk and show improvement in the ability to multitask while walking. Participants that are eligible after screening for the study will be randomized to receive Varenicline or placebo.

    ✓ Study care freePhase 2Ages 45+Learn more →
  • Dementia / Alzheimer'sParkinson's diseaseMultiple sclerosis (MS)

    Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers

    Testing safety of a PET imaging tracer in people with ALS, AD, MS, PD

    📍 UCSF · San Francisco, CA · +2 more US sites · Get directions →

    This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs. 18F-OP-801 is intended as a biomarker for PET imaging of activated microglia and macrophages in regions of neuroinflammation.

    ✓ Study care freePhase 1Ages 18–80Learn more →
  • Heart / cardiovascular disease

    Canagliflozin Targeting Vascular Inflammation

    Testing canagliflozin to reduce blood vessel inflammation in cardiovascular disease

    💵 May compensate

    📍 University of Ottawa Heart Institute · Ottawa, Ontario · Get directions →

    CANTOR SING is a pilot single center double blinded randomized study. The investigators will compare the effect of canagliflozin (300 mg daily - intervention arm) vs.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Heart / cardiovascular disease

    Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

    Testing a medicine to see its cardiovascular effects in adults on dialysis

    📍 Nephrology of North Alabama · Decatur, AL · +39 more US sites · Get directions →

    This is a two-part, phase 2b and phase 3 combined prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1: Phase 2b is a dose-finding study for CSL300 vs placebo.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Parkinson's disease

    A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease

    Testing the safety and side effects of DSP-1083 implanted in people with Parkinson’s disease

    📍 University of Kentucky Medical Center · Lexington, KY · +1 more US site · Get directions →

    The Goal of this study is to evaluate the safety, tolerability, and clinical responses following implantation of DSP-1083. Study enrolls both male and female patients in 2 cohorts.

    ✓ Study care freePhase 1Ages 40–72Learn more →
  • Parkinson's disease

    The University of Alabama at Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy

    Testing brain inflammation in people with Parkinson’s using PET scans

    📍 UAB Advanced Imaging Facility · Birmingham, AL · Get directions →

    The primary objective of this substudy is to measure the concentration and the regional brain distribution of activated brain microglia/macrophages using the PET ligand \[18F\]DPA-714 in participants enrolled in the UAB Innate and Adaptive Immunity in Parkinson's Disease (Clinical Research Core) and Longitudinal \[18F\]DPA-714 Imaging in a Parkinson Disease Cohort studies. The PET tracer \[18F\]DPA-714 binds to the 18 kDa translocator protein (TSPO, also known as the peripheral benzodiazepine receptor) in the mitochondria of activated microglia/macrophages and provides a non-invasive measure of neuroinflammation.

    ✓ Study care freePhase 1Ages 30+Learn more →
  • Heart / cardiovascular disease

    Ertugliflozin in Chronic Heart Failure

    Testing ertugliflozin and other medicines for heart failure symptoms

    📍 Yale School of Medicine · New Haven, CT · Get directions →

    The purpose of this study is to determine the effects on heart failure signs and symptoms of the use of either ertugliflozin, metolazone or placebo, in conjunction with intravenous loop diuretic use in acute settings and chronic oral loop diuretic therapy. There are two general purposes for this study.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Heart / cardiovascular disease

    Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions

    Testing stem cell treatment for safety and effects on heart disease

    📍 Southern California Hospital at Culver City / Southern California Hospital at Hollywood / Multiple US-based Sub-Investigator Sites · Culver City, CA · Get directions →

    This multi-arm, multi-site study investigates the safety, tolerability, and efficacy of stem cell therapy for the treatment of various acute and chronic conditions. Clinically observed initial findings and an extensive body of research indicate regenerative treatments are both safe and effective for the treatment of multiple conditions.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Heart / cardiovascular diseaseHigh blood pressure

    Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)

    Studying how vitamin C affects blood vessel function in obese adults with insulin resistance and

    📍 University of Kansas Medical Center · Kansas City, KS · Get directions →

    The main purpose of research is to examine and understanding the development of hypertension in obese adults with insulin resistance. Findings from our studies will identify unique mechanisms that can be targeted to limit increases in vascular dysfunction and reduce the excessively high prevalence of hypertension and risk for cardiovascular disease (CVD).

    ✓ Study care freePhase 1Ages 35–65Learn more →
  • High blood pressureCOPD (chronic lung disease)

    Pulmonary Hypertension SOLAR

    Testing a noninvasive MRI pattern to study lung blood vessel changes in pulmonary hypertension

    📍 Duke University Medical Center · Durham, NC · Get directions →

    The main goal of this study is to develop a noninvasive signature for pulmonary vascular remodeling in Group 3 PH patients, using hyperpolarized 129Xe magnetic resonance imaging (129Xe MRI). Such a signature may identify Group 3 PH responders to PAH-specific therapies.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Obesity / overweightHeart / cardiovascular diseaseHigh blood pressure

    PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis

    Testing timing of blood pressure medicines in people with obesity and high blood pressure

    📍 University of Alabama at Birmingham · Birmingham, AL · Get directions →

    Obese individuals have a higher prevalence of nocturnal hypertension and non-dipping blood pressure (BP). These conditions are associated with an increased risk of cardiovascular (CV) events and death.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Parkinson's disease

    Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease

    Testing nasal insulin and glutathione added to usual care in people with Parkinson’s

    📍 Institute for Neuroimmune Medicine · Davie, FL · +2 more US sites · Get directions →

    This study will be evaluating the safety and efficacy of insulin and glutathione in subjects with Parkinson's Disease compared to placebo.

    ✓ Study care freePhase 2Ages 30+Learn more →
  • Obesity / overweightHigh blood pressure

    Sympathetic Mechanisms in Obesity-Crossover Design

    Testing whether blocking sympathetic nerves after 2 weeks changes blood sugar in obese adults with

    📍 Vanderbilt University Medical Center · Nashville, TN · Get directions →

    We will study obese hypertensive subjects in a randomized, crossover study to determine if two weeks sympathetic blockade improves endogenous glucose production. Subjects will be studied on 3 different occasions after two weeks of receiving either placebo, amlodipine (vasodilator arm) or moxonidine (study arm).

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • DepressionParkinson's disease

    Probiotic Treatment for Depression and Associated Mood Disorders in Parkinson's Disease

    Testing whether a 12-week multi-strain probiotic can treat depression in people with Parkinson’s

    📍 Pacific Parkinson's Research Centre · Vancouver, British Columbia · Get directions →

    This study evaluates the use of an oral multi-strain probiotic in the treatment of depression in individuals with Parkinson's Disease. Participants will be randomized to either a 12-week multi-strain probiotic treatment or placebo intervention.

    ✓ Study care freePhase 2Ages 40–80Learn more →
  • Heart / cardiovascular diseaseKidney disease

    Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease

    Testing dapagliflozin with standard care on heart and lung function and blood metabolites in chronic

    📍 Northwestern University · Chicago, IL · Get directions →

    The goal of this study is to better understand the effects of a sodium-glucose transport protein 2 inhibitor, dapagliflozin, added on to standard of care on heart and lung function and circulating metabolites (substances created when our bodies break down food, drugs, or its own tissues) in patients with chronic kidney disease.

    ✓ Study care freePhase 1Ages 18–85Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults

    Testing tirzepatide to see effects on muscle and blood vessels in older adults with obesity and

    📍 University of Texas Health Science Center at San Antonio · San Antonio, TX · Get directions →

    Obesity and type 2 diabetes mellitus (T2DM) represent major public health concerns in the aging community. Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist recently approved for the treatment of T2DM and obesity has been shown to be effective at reducing weight, improving markers of T2DM control, and improving cardiovascular health.

    ✓ Study care freePhase 2Ages 50+Learn more →
  • Parkinson's disease

    A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

    Testing BHV-8000 for safety and effectiveness in adults with early Parkinson's disease

    📍 Site-049 · Birmingham, AL · +14 more US sites · Get directions →

    A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease.

    ✓ Study care freePhase 2Ages 40–85Learn more →